News | Media | Cinclus Pharma

Cinclus Pharma announces positive FDA interaction

23 Nov 2023

Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted Cinclus Pharma's proposal for the phase III program, including study design and primary endpoint for the studies. The positive outcome allows Cinclus Pharma to proceed with its phase III program.

Cinclus Pharma's phase II eGERD study in two presentations at UEG

16 Oct 2023

Two abstracts from Cinclus Pharma's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European Gastroenterology ("UEG") 14 – 17 October 2023. One of the abstracts focuses on linaprazan glurate's effectiveness, the other one on its safety.

Lennart Hansson, visionary and experienced Chairman of the Board

29 Jun 2023

Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various biotech and pharmaceutical companies. He has also worked at AstraZeneca on gastrointestinal diseases and has served on more than 30 company boards. At Cinclus Pharma, all this experience is now put to good use.